Senseonics (NYSE:SENS) Sets New 1-Year High - Should You Buy?

Senseonics Holdings, Inc. (NYSE:SENS - Get Free Report) shares reached a new 52-week high on Tuesday . The stock traded as high as $1.20 and last traded at $1.06, with a volume of 18589708 shares. The stock had previously closed at $1.13.

Analysts Set New Price Targets

SENS has been the subject of a number of research analyst reports. HC Wainwright reiterated a "buy" rating and issued a $2.00 price target on shares of Senseonics in a report on Friday, November 15th. StockNews.com assumed coverage on shares of Senseonics in a report on Thursday, December 26th. They set a "sell" rating on the stock.

Senseonics Stock Down 11.9 %

The stock has a 50 day moving average price of $0.58 and a 200 day moving average price of $0.44. The company has a market cap of $571.99 million, a P/E ratio of -7.39 and a beta of 0.64. The company has a debt-to-equity ratio of 59.17, a quick ratio of 2.38 and a current ratio of 2.47.

Senseonics (NYSE:SENS - Get Free Report) last issued its earnings results on Thursday, November 7th. The company reported ($0.04) earnings per share for the quarter, missing analysts' consensus estimates of ($0.03) by ($0.01). The business had revenue of $4.26 million for the quarter, compared to the consensus estimate of $4.02 million. Senseonics had a negative return on equity of 842.25% and a negative net margin of 362.30%. Research analysts expect that Senseonics Holdings, Inc. will post -0.14 earnings per share for the current fiscal year.

Remove Ads

Insider Transactions at Senseonics

In related news, CEO Timothy T. Goodnow purchased 315,000 shares of Senseonics stock in a transaction dated Tuesday, December 10th. The stock was acquired at an average cost of $0.31 per share, with a total value of $97,650.00. Following the completion of the transaction, the chief executive officer now directly owns 11,310,355 shares of the company's stock, valued at $3,506,210.05. This trade represents a 2.86 % increase in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CFO Frederick T. Sullivan acquired 124,933 shares of the stock in a transaction that occurred on Thursday, December 12th. The shares were bought at an average cost of $0.38 per share, for a total transaction of $47,474.54. Following the completion of the transaction, the chief financial officer now directly owns 2,478,844 shares of the company's stock, valued at $941,960.72. This represents a 5.31 % increase in their position. The disclosure for this purchase can be found here. 3.60% of the stock is currently owned by insiders.

Institutional Inflows and Outflows

Several hedge funds have recently bought and sold shares of the company. Ridgecrest Wealth Partners LLC acquired a new stake in Senseonics in the 4th quarter worth approximately $60,000. FMR LLC lifted its stake in shares of Senseonics by 48,267.2% in the third quarter. FMR LLC now owns 168,318 shares of the company's stock worth $59,000 after buying an additional 167,970 shares during the last quarter. GSA Capital Partners LLP bought a new stake in shares of Senseonics during the 3rd quarter worth $117,000. Cubist Systematic Strategies LLC grew its stake in Senseonics by 25.9% in the 2nd quarter. Cubist Systematic Strategies LLC now owns 415,404 shares of the company's stock valued at $166,000 after buying an additional 85,501 shares during the last quarter. Finally, Symmetry Partners LLC bought a new position in Senseonics in the 3rd quarter worth $164,000. 12.36% of the stock is owned by institutional investors and hedge funds.

Senseonics Company Profile

Senseonics Holdings, Inc, a medical technology company, focuses on development and manufacturing of continuous glucose monitoring (CGM) systems for people with diabetes in the United States and internationally. The company's products include Eversense, Eversense XL, and Eversense E3 that are implantable CGM systems to measure glucose levels in people with diabetes through an under-the-skin sensor, a removable and rechargeable smart transmitter, and a convenient app for real-time diabetes monitoring and management.